UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

Journal of clinical pharmacology, 2016-12, Vol.56 (12), p.1484-1499

2016

Volltextzugriff (PDF)

Genomic Characterization of Preclinical Prostate Cancer Cell Line Models

International journal of molecular sciences, 2024-06, Vol.25 (11), p.6111

2024

Volltextzugriff (PDF)

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

Molecular cancer therapeutics, 2009-09, Vol.8 (9), p.2496-2508

2009

Volltextzugriff (PDF)

Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer

Clinical cancer research, 2008-06, Vol.14 (11), p.3312-3318

2008

Volltextzugriff (PDF)

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

Clinical cancer research, 2008-07, Vol.14 (14), p.4543-4549

2008

Volltextzugriff (PDF)

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA

The oncologist (Dayton, Ohio), 2021-01, Vol.26 (1), p.e115-e129

2021

Volltextzugriff (PDF)

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Molecular cancer research, 2017-08, Vol.15 (8), p.1096-1105

2017

Volltextzugriff (PDF)

Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention

Molecular cancer research, 2006-03, Vol.4 (3), p.135-150

2006

Volltextzugriff (PDF)

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

Clinical cancer research, 2009-02, Vol.15 (4), p.1496-1503

2009

Volltextzugriff (PDF)

A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer

BJU international, 2008-09, Vol.102 (5), p.617-621

2008

Volltextzugriff (PDF)

Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel

Clinical cancer research, 2006-08, Vol.12 (15), p.4636-4640

2006

Volltextzugriff (PDF)

Androgen receptor variation affects prostate cancer progression and drug resistance

Pharmacological research, 2016-12, Vol.114, p.152-162

2016

Volltextzugriff (PDF)

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

Prostate cancer and prostatic diseases, 2019-09, Vol.22 (3), p.406-410

2019

Volltextzugriff (PDF)

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Molecular cancer therapeutics, 2021-05, Vol.20 (5), p.915-924

2021

Volltextzugriff (PDF)

Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38

Journal of clinical pharmacology, 2004-08, Vol.44 (8), p.854-860

2004

Volltextzugriff (PDF)

Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial

Endocrine-related cancer, 2022-01, Vol.29 (2), p.99-109

2022

Volltextzugriff (PDF)

GNRH2 Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy

Anticancer research, 2023-09, Vol.43 (9), p.4023-4030

2023

Volltextzugriff (PDF)

Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw

Clinical pharmacology and therapeutics, 2021-12, Vol.110 (6), p.1558-1569

2021

Volltextzugriff (PDF)

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

Molecular cancer, 2014-04, Vol.13 (1), p.91-91, Article 91

2014

Volltextzugriff (PDF)

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

Molecular pharmacology, 2015-06, Vol.87 (6), p.1006-1012

2015

Volltextzugriff (PDF)

Mapping a path for cancer precision medicine

The lancet oncology, 2017-11, Vol.18 (11), p.1444-1444

2017

Volltextzugriff (PDF)

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

Clinical cancer research, 2005-10, Vol.11 (20), p.7398-7404

2005

Volltextzugriff (PDF)

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

The Journal of clinical investigation, 2017-06, Vol.127 (6), p.2326-2338

2017

Volltextzugriff (PDF)

PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials

American journal of clinical and experimental urology, 2022-01, Vol.10 (4), p.252-257

2022

Volltextzugriff (PDF)

Genetic variation: effect on prostate cancer

Biochimica et biophysica acta, 2014-12, Vol.1846 (2), p.446-456

2014

Volltextzugriff (PDF)

1 – 25 von 312

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(264)

Publikationsform

Sprache

Englisch
(312)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment

Genomic Characterization of Preclinical Prostate Cancer Cell Line Models

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer

Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel

Androgen receptor variation affects prostate cancer progression and drug resistance

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38

Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial

GNRH2 Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy

Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells

Mapping a path for cancer precision medicine

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials

Genetic variation: effect on prostate cancer

Aktive Filter

Suchergebnisse filtern